Date Shipment Needed:	Ship To: □Patient □Prescriber
□ Nursing needed; □ Training needed ► All the supplies incl	luding syringes and needles will be dispensed if needed.

ORAL ONCOLOGY REFERRAL FORM

PATIENT INFORMATION	DATIENT INFO	OMATION									
SSN		KMATION				DOB:	le,	v: DM DE	\Moight:		
Emergency Contact:			Dhana		Allamiaa	_)St	X. U IVI U F	weight.	•	uibs. ukg.
Emergency Contact: Phone: Dea: State Lic:			Priorie.		Allergies.			Ctata		7:	
PRESCRIBER INFORMATION NPI: DEA: State Lic:		La . 4.			Dhanai	City:			-44b-d-		
Prescriber											
Peachice Name:		NFURMATI	UN		NDI	DEA			Ctoto	Lio	
Address:		oioion:			INPI.	•			State	LIC.	
Phone: Fax. Key Office Contact: Phone: Phone: DAGNOSIS INFORMATION MEDICAL ASSISSIENT		Sician.						State:		7in:	
DIAGNOSIS INFORMATION MEDICAL ASSESMENT				Fav:			nt·	State.	Dhone:	Ζιμ.	
Primary Diagnosis: CLT1.9 Castrointestinal Stromal Tumors Cl3.3 - Cl3 Metastatic Colorectal Cancer C22.0 - C22.2 - C22.7 - C22.8 Hepatocallular Carcinoma C25.9 Adenocarcinoma D19.9 Glioblastoma C25.9 Adenocarcinoma D19.9 Glioblastoma C25.9 Cutaneous T-Cell Lymphoma (Mycosis Fungoides or Sezary's Disease) C29.0 - C90.0 - C9		JEODMATI	ON / MEDICAL A	-		Rey Office Contac	JI.		FIIOHE.		
□C35 9 Adenocaroinoma of Pancreas □C34 90 Pulmonary Malignancy □C56.019 Breast Cancer □C64 9 Renal Cell Caroinoma □191.9 Glioblastoma □C73 Malignant Neoplasm of Thyrod Glotal □C38.29 ∪ C42.99 Cutaneous T-Cell Lymphoma (Mycosis Fungoides or Special Special Pulmonary Neoplasm of Thyrod Glotal □C32.10 · C92.11 · C92.12 Chronic Myeloid Leukemia □L52 Erythema Nodosum (ENL) □ Other: □C30.00 · C90.02 Multiple Myeloma □C92.10 · C92.11 · C92.12 Chronic Myeloid Leukemia □L52 Erythema Nodosum (ENL) □ Other: □C30.00 · C90.01 · C90.02 Multiple Myeloma □C92.10 · C92.11 · C92.12 Chronic Myeloid Leukemia □L52 Erythema Nodosum (ENL) □ Other: □C30.00 · C90.01					R - C10 Motos	tatic Colorectal Can	car DC2	2 0 - C22 2 -	C22.7 - C	22 8 Henatocellul	ar Carcinoma
□ Please check if enrolling in copay card Copay ID: PRESCRIPTION INFORMATION Medication mg QTY. SIG. Refills Medication mg QTY. SIG. Refills □ Affinitor □ Sinyrycel □ Sinyrycel □ Dassulfi □ Sitvarga □ □ Sitvarga □ Capecitabine □ Date □ Date □ Date □ Erivedge □ Date □ □ Date □ Date □ Date □ Date □ Date □ Date □ □ Date □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □	□C73 Malignant Neoplasm of Thyroid Gland □C82.90 - C82.99 Čutanéous T-Cell Lymphoma (Mycosis Fungoides or Sezary's Disease) □C90.00 - C90.01 - C90.02 Multiple Myeloma □C92.10 - C92.11 - C92.12 Chronic Myeloid Leukemia □L52 Erythema Nodosum (ENL) □ Other: □ Has patient been treated <i>previously</i> for this condition? □Yes □No Medication(s): □ Cancer Stage: □Stage 0 □Stage I □Stage II □Stage IV □Other □ □ Is patient <i>currently</i> on therapy? □Yes □No Medication(s): □ □ Will patient stop taking the above medication(s) before starting the new medication? □Yes □No If yes: □ □ How long should patient wait before starting the new medication? □Yes □No If yes: □ □ Other medications patient is currently taking including OTC medications with dosage and direction (or fax medication profile): INSURANCE INFORMATION										
□ Please check if enrolling in copay card Copay ID: PRESCRIPTION INFORMATION Medication mg QTY. SIG. Refills Medication mg QTY. SIG. Refills □Sprycel □Spryc	COPAY CARD E	ENROLLME	NT								
Medication mg QTY. SIG. Refills Medication mg QTY. SIG. Refills				d Copay ID:							
Dasoulif											
Dasoulif	Madiastian	ma	OTV	SIC	Dofillo	Medication		OTV		SIC	Dofillo
Descritabine		ilig	QII.	310.	iteilis		ilig	QII.		310.	IVEIIIIS
Date											
DErivedge											
□Erleada □Tarceva □Gleevec □Tasigna □Hycamtin □Temodar □Inlyta □Temozolomide □Kisqali □Topotecan □Mekinist □Tykerb □Nerlynx □Votrient □Nexavar □Xalkori □Nubeqa □Xtandi □Odomzo □Zytiga □Rydapt □Dosage: □Aloxi □Akynzeo □Dolasetron □Emend □Granisetron □Prochlorperazine □Ondansetron □Other: □Dosage: □Dosage: QTY: Refills: Supportive Agents: □Neupogen □Neulasta □Procrit □Epogen □Aranesp □Prothelial □Loperamide □Other:	•										
□Gleevec □Tasigna □Hycamtin □Temodar □Inlyta □Temozolomide □Kisqali □Topotecan □Mekinist □Tykerb □Nerlynx □Votrient □Nexavar □Xalkori □Nubeqa □Xtandi □Odomzo □Zytiga □Rydapt □Cher: □Dosage: □Chemo-induced NV □Radiation-induced NV □Adiation-induced											
□Hycamtin □Temodar □Inlyta □Temozolomide □Kisqali □Topotecan □Mekinist □Tykerb □Nerlynx □Votrient □Nubeqa □Xalkori □Nubeqa □Xtandi □Odomzo □Zytiga □Rydapt □Chemo-induced N/V □Radiation-induced N/V □Aloxi □Akynzeo □Dolasetron □Emend □Granisetron □Prochlorperazine □Ondansetron □Other: □TY: Refills: □Dosage: QTY: Refills: Supportive Agents: □Neupogen □Neulasta □Procrit □Epogen □Aranesp □Prothelial □Loperamide □Other:											
□Inlyta □Temozolomide □Kisqali □Topotecan □Mekinist □Tykerb □Nerlynx □Votrient □Nexavar □Xalkori □Nubeqa □Xtandi □Odomzo □Zytiga □Rydapt □Nubeqa □Rydapt □Tykerb □Alpxi □Nubeqa □Rydapt □Tykerb □Alpxi □Nubeqa □Rydapt □Tykerb □Nubeqa □Tykerb □Tykerb □Tykerb □Tykerb □Tykerb □Tykerb □Tykerb □Tyker											
□Kisqali □Topotecan □Mekinist □Tykerb □Nerlynx □Votrient □Nexavar □Xalkori □Nubeqa □Xtandi □Odomzo □Zytiga □Rydapt □Cher: □Other: □Dosage: □Aloxi □Akynzeo □Dolasetron □Emend □Granisetron □Prochlorperazine □Ondansetron □Other: □TY: Refills: □Dosage: QTY: Refills: Supportive Agents: □Neupogen □Neulasta □Procrit □Epogen □Aranesp □Prothelial □Loperamide □Other:											
□Mekinist □Tykerb □Nerlynx □Votrient □Nexavar □Xalkori □Nubeqa □Xtandi □Odomzo □Zytiga □Rydapt □Chemo-induced N/V □Aloxi □Akynzeo □Dosage: □Chemo-induced N/V □Aloxi □Akynzeo □Dosage: □Chemo-induced N/V □Dosage: □Chemo-induced N/V □Refills: □Chemo-induced N/V □Neupoge □Chemo-induced N/V □Neupoge <td></td>											
□Nerlynx □Votrient □Nexavar □Xalkori □Nubeqa □Xtandi □Odomzo □Zytiga □Rydapt □Dosage: □Aloxi □Akynzeo □Dolasetron □Emend □Granisetron □Prochlorperazine □Ondansetron □Other: □Chemo-induced N/V □Radiation-induced N/V □Radiation-induced N/V □Radiation-induced N/V □Aloxi □Akynzeo □Dolasetron □Emend □Granisetron □Prochlorperazine □Ondansetron □Other: □Chemo-induced N/V □Radiation-induced N/V □Radiation-indu	-					•					
□Nexavar □Xtalkori □Nubeqa □Xtandi □Odomzo □Zytiga □Rydapt □Dosage: □Other: □Dosage: Antimetics: □Chemo-induced N/V □Radiation-induced N/V □Radi											
□Nubeqa □Xtandi □Odomzo □Zytiga □Rydapt □Dosage:											
□Odomzo □Zytiga □Rydapt □Dosage: QTY: Refills: Antimetics: □Chemo-induced N/V □Radiation-induced N/V □Aloxi □A											
□ Other: □ Dosage: QTY: Refills: Antimetics: □ Chemo-induced N/V □ Radiation-induced N/V □ Aloxi □ Chemo-induced N/V □ Refills: □ Dosage: QTY: Refills: Supportive Agents: □ Neupogen □ Neulasta □ Procrit □ Epogen □ Aranesp □ Prothelial □ Loperamide □ Other: □ Neupogen □ Neulasta □ Procrit □ Epogen □ Aranesp □ Prothelial □ Loperamide □ Other: □ Neupogen □ Neulasta □ Procrit □ Epogen □ Aranesp □ Prothelial □ Loperamide □ Other: □ Neupogen □ Neulasta □ Procrit □ Epogen □ Aranesp □ Prothelial □ Loperamide □ Other: □ Neupogen □ Neupogen □ Neulasta □ Procrit □ Epogen □ Aranesp □ Prothelial □ Loperamide □ Other: □ Neupogen □ Neulasta □ Procrit □ Epogen □ Aranesp □ Prothelial □ Loperamide □ Other: □ Neupogen □ Neulasta □ Procrit □ Epogen □ Aranesp □ Prothelial □ Loperamide □ Other: □ Neupogen □ Neulasta □ Procrit □ Epogen □ Aranesp □ Prothelial □ Loperamide □ Other: □ Neupogen □ Neulasta □ Procrit □ Epogen □ Aranesp □ Prothelial □ Loperamide □ Other: □ Neupogen □ Neulasta □ Procrit □ Epogen □ Aranesp □ Prothelial □ Loperamide □ Other: □ Neupogen □ Neulasta □ Procrit □ Epogen □ Aranesp □ Prothelial □ Loperamide □ Other: □ Neupogen □ Neulasta □ Procrit □ Epogen □ Aranesp □ Prothelial □ Loperamide □ Other: □ Neupogen □ Neulasta □ Procrit □ Epogen □ Aranesp □ Prothelial □ Loperamide □ Other: □ Neupogen □ Neulasta □ Procrit □ Epogen □ Aranesp □ Prothelial □ Loperamide □ Other: □ Neupogen □ Neulasta □ Procrit □ Epogen □ Aranesp □ Prothelial □ Loperamide □ Other: □ Neupogen □ Neulasta □ Procrit □ Epogen □ Procrit □ Epogen □ Neulasta □ Procrit □ Epogen □ Neulasta □ Procrit □ Epogen □ Neulasta □ Procrit □ Epogen □ Procrit □ Epogen □ P											
□Other: □Dosage: QTY: Refills: Antimetics: □Chemo-induced N/V □Radiation-induced N/V □Aloxi □Akynzeo □Dolasetron □Emend □Granisetron □Prochlorperazine □Ondansetron □Other: QTY: Refills: □Dosage: QTY: Refills: Supportive Agents: □Neulpogen □Neulasta □Procrit □Epogen □Aranesp □Prothelial □Loperamide □Other:									I		
Antimetics: Chemo-induced N/V Aloxi Akynzeo Dolasetron Emend Granisetron Prochlorperazine Ondansetron Other: QTY: Refills: Supportive Agents: Neupogen Neulasta Procrit Epogen Aranesp Prothelial Loperamide Other: Oth		l	l.							271	5 511
□Dosage: QTY: Refills: Supportive Agents: □Neulasta □Procrit □Epogen □Aranesp □Prothelial □Loperamide □Other:											
□Neupogen □Neulasta □Procrit □Epogen □Aranesp □Prothelial □Loperamide □Other:								QTY:	Refills:		
	□Neupogen □Neulasta □Procrit □Epogen □Aranesp □Prothelial □Loperamide □Other:								QTY:	Refills:	

Prescriber's Signature: Date: ☐ DAW (Dispense as Written)